Phosphoinositide 3-kinase as a therapeutic target in angiogenic disease.


Journal

Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707

Informations de publication

Date de publication:
11 2023
Historique:
received: 22 06 2022
revised: 30 08 2023
accepted: 05 09 2023
medline: 13 11 2023
pubmed: 17 9 2023
entrez: 16 9 2023
Statut: ppublish

Résumé

Phosphoinositide 3-kinases (PI3Ks) generate lipids that control multitudinous intracellular cell signaling events which participate in cell survival and proliferation. In addition, PI3K signaling also contributes to metabolism, immunity, angiogenesis and cardiovascular homeostasis, and many diseases. The diverse actions of PI3K stem from the existence of their various isoforms and a variety of protein effectors. Hence, PI3K isoform-specific inhibitors have already achieved a wonderful effect on treating cancer. Herein, we summarize the molecular mechanism of PI3K inhibitors in preventing the permeability of vessels and neovascularization. Additionally, we briefly illustrate how PI3K signaling modulates blood vessel growth and discuss the different roles that PI3K isoforms play in angiogenesis.

Identifiants

pubmed: 37716399
pii: S0014-4835(23)00267-1
doi: 10.1016/j.exer.2023.109646
pii:
doi:

Substances chimiques

Phosphatidylinositol 3-Kinase EC 2.7.1.137
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Phosphoinositide-3 Kinase Inhibitors 0
Protein Isoforms 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109646

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Auteurs

Wenyi Wu (W)

Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Ophthalmology, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. Electronic address: wenyi_wu@csu.edu.com.

Xiaobo Xia (X)

Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Ophthalmology, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Luosheng Tang (L)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Jing Luo (J)

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Siqi Xiong (S)

Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China; Hunan Key Laboratory of Ophthalmology, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Gaoen Ma (G)

Department of Ophthalmology, The First Affiliated Hospital of Hainan Medical University, Haikou, 571199, China. Electronic address: 15757826611@163.com.

Hetian Lei (H)

Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, China. Electronic address: leithetian18@hotmail.com.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin
1.00
Animals Mice Immunity, Innate Interneurons Synapses

Classifications MeSH